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Anti–dengue virus immunoglobulin M kits were evaluat-
ed. Test sensitivities were 21%–99% and speciﬁ  cities were 
77%–98% compared with reference ELISAs. False-positive 
results were found for patients with malaria or past dengue 
infections. Three ELISAs showing strong agreement with 
reference ELISAs will be included in the World Health Orga-
nization Bulk Procurement Scheme.
A
n estimated 2.5–3 billion persons live in tropical and 
subtropical regions where dengue virus (DENV) is 
transmitted (1–3). Absence of inexpensive and accurate 
tests to diagnose dengue makes case management, surveil-
lance, and outbreak investigation difﬁ  cult. During infec-
tion, immunoglobulin (Ig) M against DENV can often be 
detected ≈5 days after onset of fever (4–6). First-time (pri-
mary) DENV infections typically have a stronger and more 
speciﬁ  c IgM response than subsequent (secondary) infec-
tions, for which the IgM response is low compared with a 
strong IgG response. These patterns underscore the need 
for evaluating the performance of commercially available 
tests, especially for diagnosis of secondary DENV infec-
tions (7–10).
The Study
To provide independent evaluation of dengue diagnostic 
tests, the United Nations International Children’s Emergen-
cy Fund/United Nations Development Programme/World 
Bank/World Health Organization Special Programme for 
Research and Training in Tropical Diseases and the Pedi-
atric Dengue Vaccine Initiative established a network of 7 
laboratories based on criteria related to dengue expertise of 
the principal investigator, and type, capacity, management 
of the laboratory. The laboratories contributed serum speci-
mens for the evaluation panel and conducted the evalua-
tion. The 7 laboratories were located at Mahidol University 
(Bangkok, Thailand), Cho Quan Hospital (Ho Chi Minh 
City, Vietnam), Institut Pasteur (Phnom Penh, Cambodia), 
University of Malaya (Kuala Lumpur, Malaysia), Centers 
for Disease Control and Prevention (CDC) (San Juan, PR, 
USA), Instituto Medicina Tropical Pedro Kouri (Havana, 
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Table 1. Panels used for evaluation of 350 serum samples from 
patients with positive and negative results for IgM to DENV* 
Evaluation panel  No. samples 
DENV IgM positive 
  From primary infections  27
 From  secondary  infections  154
 Total  positive  181†
DENV IgM negative 
  DENV positive/DENV IgM negative  19
 DENV  IgG  positive  7
Related flavivirus IgM positive 
  West Nile virus positive  25
  Yellow fever virus positive  4
Related flavivirus IgG positive 
  West Nile virus positive  1
  Yellow fever virus positive  10
  St. Louis encephalitis virus positive  2
  Japanese encephalitis virus positive  10
Febrile illness 
  Lyme disease IgG positive  9
 Malaria  31
  New World hantavirus IgM positive  7
Systemic conditions 
 Rheumatoid  factor  6
  Systemic lupus erythematosus  2
Healthy persons‡ 
 Negative  36
Total negative  169
*DENV, dengue virus; Ig, immunoglobulin. 
†No. serum samples identified as serotype specific: 26 DENV-1, 19 
DENV-2, 13 DENV-3, and 7 DENV-4. Serotype was not identified for 116 
samples. 
‡From areas where dengue is not endemic. Anti–Dengue Virus IgM Tests
Cuba), and Instituto Nacional Enfermedades Virales Hu-
manas Dr. Julio I. Maiztegui (Buenos Aires, Argentina). 
Laboratories at Mahidol University and CDC acted as ref-
erence laboratories by providing samples for proﬁ  ciency 
testing among laboratories and for assembling and validat-
ing the evaluation panel.
The evaluation panel consisted of 350 well-charac-
terized serum specimens (Table 1). Specimens positive 
for IgM against DENV were obtained from patients with 
primary and secondary infections and represented all 4 
DENV serotypes. IgM levels were determined by reference 
standard ELISAs used by CDC and the Armed Forces Re-
search Institute of Medical Science (Bangkok, Thailand) 
(6,7). Positive samples were selected based on optical den-
sity (OD) and were weighted toward low and medium ODs. 
Negative control samples included serum samples from 
healthy persons in areas where dengue is not endemic and 
from patients with other ﬂ  avivirus infections, febrile illness 
of other causes, or systemic conditions. Results were con-
ﬁ  rmed as negative for IgM antibodies against DENV by 
using predetermined reference standards. Additionally, 20 
anti-DENV IgM-negative specimens were obtained from 
SeraCare Diagnostics (Milford, MA, USA). Panel speci-
mens were coded, heat-inactivated, aliquoted, and lyo-
philized; 1 aliquot was retested by the reference laborato-
ries after reconstitution.
Letters of interest and the evaluation protocol were 
sent to 20 dengue kit manufacturers. Six companies 
agreed to participate and provided 4 rapid diagnostic tests 
(RDTs) and 5 microplate ELISAs. Test characteristics are 
summarized in Table 2. Price per test ranged from US $3 
to $15.
Laboratories evaluated the kits for sensitivity and 
speciﬁ  city by using the evaluation panel. For each test, 
kappa coefﬁ  cient values were determined to assess agree-
ment of mean sensitivity and speciﬁ  city of each test with 
the reference standard. A test of homogeneity was used to 
determine extent of agreement of results among sites.
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Table 2. Characteristics of 9 tests used for detection of IgM against dengue virus* 
ELISAs
Test name  Dengue IgM 
capture
Pathozyme dengue 
M
Pathozyme dengue 
M capture 
Dengue fever virus 
IgM capture 
DxSelect
Dengue IgM 
capture
Company, location  Panbio Diagnostics, 
Windsor,
Queensland,
Australia 
Omega Diagnostics, 
Alva, UK 
Omega Diagnostics Focus Diagnostics, 
Cypress, CA, USA 
Standard
Diagnostics,
Kyonggi-do, South 
Korea
Detection method  IgM capture  Indirect IgM 
detection
IgM capture  IgM capture  IgM capture 
Format 12 strips of 8 wells  12 strips of 8 wells  12 strips of 8 wells  12 strips of 8 wells  12 strips of 8 wells 
No. tests/package 96 96 96 96 96
Antigen Recombinant DENV 
1–4
Purified DENV 2  DENV 1–4  DENV 1–4  DENV 1–4 
Sample volume, PL 10 10 20 10 10
Total incubation time  130 min at 37°C  120 min at 37°C  110 min at 37°C  240 min at room 
temperature 
130 min at 37°C 
Storage conditions, °C  2–30 2–8 2–8 2–8 2–8
Rapid diagnostic tests 
Test name  Dengue duo cassette  Hapalyse dengue-M PA 
kit
Dengucheck WB  SD dengue IgG/IgM 
Company, location  Panbio Diagnostics  Pentax, Tokyo, Japan  Zephyr Biomedicals, 
Panaji, India 
Standard Diagnostics 
Assay principle  Lateral flow  Particle agglutination Lateral flow  Lateral flow 
Target antibody  IgM and IgG  IgM IgM and IgG  IgM and IgG 
Format Cassette 12 strips of 8 wells  Cassette Cassette
No. tests/package 25 96 25 25
Antigen Recombinant DENV 1–4  DENV 1–4  Recombinant DENV 
(serotype not specified) 
Recombinant DENV 1–4 
envelope protein 
Specimen type  Serum, plasma, or whole 
blood
Serum or plasma  Serum, plasma, or whole 
blood
Serum or plasma 
Volume of sample 
required, PL
10 1 5 5
Duration of test, min  15 90 15 15–20
Storage conditions, °C  2–30 2–8 4–30 1–30
Additional equipment 
required
No Yes (e.g., micropipette)  No No
*Ig, immunoglobulin; DENV, dengue virus. Mean sensitivities of ELISAs were 61.5%–99.0%, and 
speciﬁ  cities were 79.9%–97.8% (Figure 1, panels A and 
B). Tests from Panbio Diagnostics (Windsor, Queensland, 
Australia), Focus Diagnostics (Cypress, CA, USA), and 
Standard Diagnostics (Kyonggi-do, South Korea) showed 
signiﬁ  cantly higher mean sensitivities (99.0%, 95% conﬁ  -
dence interval [CI] 98.4%–99.5%; 98.6%, 95% CI 98.0%–
99.2%; and 97.6%, 95% CI 96.8%–98.4%, respectively) 
than 2 tests from Omega Diagnostics (Alva, UK) (62.3% 
and 61.5%; p<0.0001 for all comparisons). The Omega 
Pathozyme Capture test showed signiﬁ  cantly higher mean 
speciﬁ  city (97.8%, 95% CI 97.0%–98.6%) than the other 
ELISAs (79.9%–86.6%; p≤0.02 for all comparisons). The 
Focus, Panbio, and Standard ELISAs showed strong agree-
ment with the reference standard (kappa values 0.81–0.85). 
Kappa values for Omega kits were below the acceptable 
range (0.46 and 0.59). Site-to-site variation for ELISAs 
was not signiﬁ  cant (homogeneity >0.05).
Mean sensitivities of RDTs were 20.5%–97.7%, and 
speciﬁ  cities were 76.6%–90.6% (Figure 1, panels C and 
D). None had an acceptable kappa value for overall per-
formance compared with reference methods. The Pentax 
(Tokyo, Japan) test had signiﬁ  cantly higher mean sensitiv-
ity (97.7%, 95% CI 96.9%–98.5%) than all other RDTs 
(p<0.0001 for all comparisons), but lowest mean speci-
ﬁ   city (76.6%, 95% CI 74.1%–79.0%; p<0.0001 for all 
comparisons) and high false-positive rates for malaria and 
anti-DENV IgG specimens (Figure 2). Panbio and Stan-
dard tests showed high mean speciﬁ  cities (90.6%, 95% CI 
88.9%–92.3%, and 90.0%, 95% CI 88%.3–91.7%) with 
different mean sensitivities (77.8%, 95% CI 75.5%–80.1%, 
and 60.9%, 95% CI 58.2%–63.6%).
Conclusions
This laboratory-based evaluation used a serum panel 
to determine the ability of 9 commercially available anti-
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Figure 1. A) Sensitivity and B) speciﬁ  city of 5 microplate ELISAs used at laboratories in 7 countries for detecting immunoglobulin (Ig) M 
against dengue virus compared with reference solid-phase IgM antibody-capture ELISAs used by the Centers for Disease Control and 
Prevention (Atlanta, GA, USA) and the Armed Forces Research Institute of Medical Science (Bangkok, Thailand). Mean sensitivities 
and speciﬁ  cities for the 5 tests are shown in parentheses. C) Sensitivity and D) speciﬁ  city of 4 rapid diagnostic tests used at laboratories 
in 7 countries for detecting IgM against dengue virus compared with solid-phase IgM antibody-capture ELISAs. Mean sensitivities and 
speciﬁ  cities for the 4 tests are shown in parentheses. Anti–Dengue Virus IgM Tests
DENV IgM tests to detect low levels of IgM and to de-
termine speciﬁ  city against pathogens that often cocirculate 
with DENV. Field trials are needed to determine the perfor-
mance and utility of these tests in a local context.
Of the 5 ELISA kits evaluated, 3 (Focus, Panbio, and 
Standard) showed strong agreement with reference stan-
dard results and were consistent across all evaluation sites. 
Of concern are false-positive results shown by some tests 
on sera that were anti-DENV IgM negative but malaria 
positive, anti-DENV IgG positive, or rheumatoid factor 
positive. The laboratory at Mahidol University also tested 
the kits against 12 serum samples from patients with lep-
tospirosis. The Panbio ELISA showed cross-reactivity with 
58% of these samples, and the Focus ELISA showed cross-
reactivity with 25%. Further studies are needed to elucidate 
the cause of this cross-reactivity.
Technicians were asked to score tests’ user-friendli-
ness. All RDTs scored higher than ELISAs, and the Panbio 
RDT scored highest.
Limitations of anti-DENV IgM tests include their in-
ability to identify the infecting DENV type and potential 
antibody cross-reactivity with other ﬂ  aviviruses (11,12). 
However, cross-reactivity to related viruses did not appear 
to be a problem with these tests. IgM tests can be useful 
for surveillance and support diagnosis of DENV infection 
in conjunction with clinical symptoms, medical history, 
and other epidemiologic information (13). Because IgM 
persists for >60 days, IgM assays should not be used in 
dengue-endemic countries as conﬁ  rmatory tests for current 
illness. Presence of IgM indicates that a dengue infection 
has occurred in the past 2–3 months.
This evaluation has several limitations. Test perfor-
mance was compared with reference laboratory assay re-
sults, which may be less sensitive than commercial assays, 
leading to some results being misclassiﬁ  ed as false posi-
tive. Speciﬁ  city of these tests may be higher in a ﬁ  eld set-
ting than in this evaluation because not all potential causes 
of false-positive results would be present. The panel con-
sisted of a high proportion of specimens from persons with 
secondary DENV infections. Thus, the panel was weighted 
toward lower anti-DENV IgM levels. However, this feature 
reﬂ  ects the situation in most dengue-endemic countries. 
Thus, tests that performed well against this panel could be 
expected to perform well in these diagnostic settings. We 
could not comprehensively evaluate whether the kits could 
detect primary infections with all 4 DENVs because all 
DENV types were not represented in the panel.
Data from this evaluation have been provided to the 
manufacturers and WHO member states. On the basis of 
these results, ELISAs from Focus, Panbio, and Standard 
Diagnostics will be included in the WHO Bulk Procure-
ment Scheme. Technical discussions are ongoing to deter-
mine how tests might be improved to accelerate availability 
of useful methods for dengue case management, surveil-
lance, and disease control.
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